Simplici-T1 is an adaptive Phase 1b/2 study being conducted with support from JDRF HIGH POINT, N.C. --(BUSINESS WIRE)--Mar. 22, 2018-- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced the completion of Phase 1b of Simplici-T1, an adaptive Phase 1b/2 study assessing the pharmacokinetics,
HIGH POINT, N.C. --(BUSINESS WIRE)--Feb. 27, 2018-- vTv Therapeutics Inc. (Nasdaq:VTVT) today provided a corporate update and reported financial and operational results for the fourth quarter and full year that ended December 31, 2017 . “We made tremendous progress across the spectrum of our
HIGH POINT, N.C. --(BUSINESS WIRE)--Dec. 21, 2017-- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC has entered into a global licensing agreement with Reneo Pharmaceuticals , a privately-held biotechnology company focused on developing treatments for orphan diseases.
HIGH POINT, N.C. --(BUSINESS WIRE)--Dec. 21, 2017-- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC has entered into a licensing agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“Huadong Pharmaceutical”) , a wholly-owned subsidiary of Huadong Medicine
HIGH POINT, N.C. --(BUSINESS WIRE)--Nov. 13, 2017-- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that the Company will host a key opinion leader (KOL) presentation and webcast focused on the current state of clinical development in Alzheimer’s disease in New York City on Thursday, November
As Part of Industry Partnership with JDRF HIGH POINT, N.C. --(BUSINESS WIRE)--Nov. 8, 2017-- vTv Therapeutics Inc. (Nasdaq: VTVT) announced today the initiation of simplici-T1, an adaptive Phase1b/2 study assessing the pharmacokinetics, pharmacodynamics, safety, and tolerability of TTP399 in adult
HIGH POINT, N.C. --(BUSINESS WIRE)--Nov. 1, 2017-- vTv Therapeutics Inc. ( vTv Therapeutics ) (Nasdaq:VTVT) today provided a corporate update and reported financial and operational results for the third quarter ended September 30, 2017 . “We’ve made significant progress in the third quarter of 2017
-- Azeliragon is the only receptor for advanced glycation endproducts (RAGE) antagonist in clinical development for Alzheimer’s disease -- HIGH POINT, N.C. --(BUSINESS WIRE)--Oct. 30, 2017-- vTv Therapeutics Inc. (Nasdaq:VTVT), today announced that the Company will present three posters on clinical
HIGH POINT, N.C. --(BUSINESS WIRE)--Sep. 7, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today announced that additional analysis from a Phase 2 clinical study of TTP273, an investigational, oral small molecule GLP-1 receptor (GLP-1R) agonist for the treatment of type 2 diabetes will be
vTv Therapeutics and JDRF enter into a $6 million industry partnership to explore the effect of liver-selective glucokinase activator TTP399 as an insulin-adjunctive therapy in type 1 diabetes HIGH POINT, N.C. --(BUSINESS WIRE)--Sep. 6, 2017-- vTv Therapeutics Inc.